Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Journal of Viral Hepatitis|May 22, 2020
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohortVictor de Lédinghen, Clovis Lusivika-Nzinga, Jean-Pierre Bronowicki, et al.
HIV Medicine|August 17, 2021
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysisMathieu Chalouni, Stanislas Pol, Philippe Sogni, et al.
Clinics and Research in Hepatology and Gastroenterology|February 1, 2015
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC studyFrançois Bailly, Victor Virlogeux, Cécilie Dufour, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2017
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE StudyVictor de Lédinghen, Claire Laforest, Christophe Hézode, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2024
Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre StudyCarine Nicolas, Quentin Domas, Stanislas Pol, et al.
British Journal of Clinical Pharmacology|May 29, 2015
Liver transplant associated with paracetamol overdose: results from the seven-country SALT studySinem Ezgi Gulmez, Dominique Larrey, Georges-Philippe Pageaux, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitisVlad Ratziu, Pierre Bedossa, Sven M Francque, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Journal of Hepatology|December 13, 2006
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virusSonia Molina, Valérie Castet, Chantal Fournier-Wirth, et al.
Alimentary Pharmacology & Therapeutics|September 24, 2024
Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAMLina Hountondji, Stéphanie Faure, Pascale Palassin, et al.
Pageof 14